Securities code: 688289 securities abbreviation: Sansure Biotech Inc(688289) Announcement No.: 2022-009 Sansure Biotech Inc(688289) announcement on termination of share reduction plan and result of share reduction by more than 5% of shareholders
The board of directors shall not be liable for any misrepresentation, omission or material misrepresentation of the contents of this announcement or the truthfulness and completeness of the relevant legal statements of the company. Important content tips:
Basic information of shareholders’ shareholding before the implementation of this reduction plan
The total number of shares held by Mr. Zhu Jinwei (hereinafter referred to as “Mr. Zhu Jinwei”) before the implementation of the “828.89 {” share reduction plan “, accounting for 2889% of the total number of shares of the company. The shares held by Mr. Zhu Jinwei are the shares of the company before its initial public offering and listing on the science and innovation board. They have been listed and circulated since August 30, 2021.
Remedies for non-compliance with commitments
When reducing his holdings through block trading, Mr. Zhu Jinwei did not comply with the commitments in the prospectus for initial public offering of shares and listing on the science and innovation board. He himself deeply reflected on the negligence in the reduction process and expressed sincere apology for the adverse impact on the company and the market caused by this behavior. At the same time, Mr. Zhu Jinwei took active remedial measures and promised to repurchase the 4600000 shares previously reduced through block trading from May 27, 2022 to December 30, 2022 after the expiration of the short-term trading restriction period.
Implementation results of share reduction plan
On November 6, 2021, the company disclosed the announcement of share reduction plan of shareholders and directors holding more than 5% of Sansure Biotech Inc(688289) through centralized bidding (Announcement No.: 2021-078). Mr. Zhu Jinwei plans to reduce his holding of no more than 2500000 shares of Shengxiang Jinyu Bio-Technology Co.Ltd(600201) through centralized bidding transaction. As of the disclosure date of this announcement, Mr. Zhu Jinwei has reduced 1200000 shares by means of centralized bidding and 4600000 shares by means of block trading, with a total reduction of 5800000 shares. After the reduction, the number of shares held by Mr. Zhu Jinwei is 28228493 shares, accounting for 20% of the total share capital of the company
The proportion is 7.06%. For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) on November 30, 2021 and December 16, 2021 The Sansure Biotech Inc(688289) suggestive announcement on the reduction of shareholders holding more than 5% to 1% (Announcement No.: 2021-087) and the suggestive announcement of Shengxiang Biotechnology Co., Ltd. on the reduction of shareholders holding more than 5% (Announcement No.: 2021-094) disclosed on the. Since Mr. Zhu Jinwei failed to comply with the commitments in the prospectus for initial public offering and listing on the science and Innovation Board on the reduction of shares during the reduction of shares of the company through block trading, he now terminates the disclosed plan to reduce shares of the company through centralized bidding trading.
1、 Basic information of the reducing entity before the reduction
Shareholder name shareholder identity shareholding number (shares) shareholding proportion current shareholding source
More than 5% of Zhu Jinwei’s shares were not obtained before the IPO, and 8.51% were obtained: a major shareholder of 34028493 shares
The above reduction subjects have no concerted action.
2、 Implementation results of centralized bidding reduction plan
(I) major shareholders and directors, supervisors and senior executives disclose the implementation results of the centralized bidding reduction plan due to the following matters:
Other circumstances: early termination
reduce one’s shares in a listed company
Current price of reduced number of shares
Eastern volume reduction period reduction interval reduction total amount of reduction reduction completed number of shares held
Inter name (share) proportion mode (yuan amount (yuan) situation (share) proportion
Weigh/
Shares)
Zhu 1200, 0.30, 2021 / 11 centralized 56.0, 68703,6 unfinished: 28228, 7.06
Jin 000% / 29 ~ bidding 6-50 1300,00 493%
Wei 2021 / 11 trading 57.7 0 shares
/30 4
(II) whether the actual reduction is consistent with the previously disclosed reduction plan and commitment □ yes √ no Mr. Zhu Jinwei reduced 4600000 shares through block trading on November 26, 2021, with a unit price of 45.97 yuan per share, and a total reduction amount of 211462000 yuan. The transaction price of the above transaction is lower than the company’s offering price, which violates the commitment on the reduction statement in the prospectus of Sansure Biotech Inc(688289) initial public offering and listing on the science and innovation board.
Mr. Zhu Jinwei deeply reflected on the negligence in the process of this reduction and expressed sincere apology for the adverse impact on the company and the market caused by this behavior. At the same time, Mr. Zhu Jinwei took active remedial measures and promised to repurchase the 4600000 shares reduced through block trading from May 27, 2022 to December 30, 2022 after the expiration of the short-term trading restriction period, and has compensated Sansure Biotech Inc(688289) with the difference amount of 15.5710 million yuan corresponding to his reduction of corresponding shares on January 5, 2022.
(III) when the reduction time interval expires, whether the reduction has not been implemented □ not implemented √ implemented
(IV) whether the actual reduction has not reached the minimum reduction quantity (proportion) of the reduction plan □ not reached √ reached (V) whether the reduction plan is terminated in advance √ yes □ no
As the transaction price of the aforesaid transaction of Mr. Zhu Jinwei was lower than the company’s offering price, he failed to comply with the commitment on the reduction of shares in the prospectus of Sansure Biotech Inc(688289) initial public offering and listing on the science and Innovation Board (see the company’s website of Shanghai Stock Exchange (www.sse. Com. CN.) on August 24, 2020) Mr. Zhu Jinwei’s plan to reduce his shares in the company through centralized bidding transaction is terminated.
It is hereby announced.
Sansure Biotech Inc(688289) board of directors February 19, 2022
